Community Schedule

You are currently viewing November 2024

2 results showing for: 'pneumococcal'

Pneumococcal (PCV13) conjugate vaccine

- Only on a prescription
- No patient co-payment payable

Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml syringe
- Brand Fully subsidised brand. Prevenar 13
- Pharmacode2383047
- Subsidy $0.00
- Measure / Qty per 1
- Brand Fully subsidised brand. Prevenar 13
- Pharmacode2451085
- Subsidy $0.00
- Measure / Qty per 10
Prevenar 13 to be Principal Supply on 1 December 2024

Any of the following:
1. A course of three doses for previously unvaccinated children up to the age of 59 months inclusive; or
2. Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10; or
3. Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high risk children aged under 5 years with any of the following:
  1. on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
  2. primary immune deficiencies; or
  3. HIV infection; or
  4. renal failure, or nephrotic syndrome; or
  5. who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
  6. cochlear implants or intracranial shunts; or
  7. cerebrospinal fluid leaks; or
  8. receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
  9. chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
  10. pre term infants, born before 28 weeks gestation; or
  11. cardiac disease, with cyanosis or failure; or
  12. diabetes; or
  13. Down syndrome; or
  14. who are pre-or post-splenectomy, or with functional asplenia; or
4. Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency; or
5. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
Contractors will be entitled to claim payment from the Funder for the supply of Pneumococcal (PCV13) conjugate vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Pneumococcal (PCV13) conjugate vaccine listed in the Pharmaceutical Schedule.
Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Pneumococcal (PPV23) polysaccharide vaccine

[Xpharm]

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)
- Brand Fully subsidised brand. Pneumovax 23
- Pharmacode2478838
- Subsidy $0.00
- Measure / Qty per 1
Pneumovax 23 to be Principal Supply on 1 December 2024

Either:

Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
All of the following:
1. Patient is a child under 18 years for (re-)immunisation; and
2. Treatment is for a maximum of two doses; and
3. Any of the following:
  1. on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
  2. with primary immune deficiencies; or
  3. with HIV infection; or
  4. with renal failure, or nephrotic syndrome; or
  5. who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
  6. with cochlear implants or intracranial shunts; or
  7. with cerebrospinal fluid leaks; or
  8. receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
  9. with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
  10. pre term infants, born before 28 weeks gestation; or
  11. with cardiac disease, with cyanosis or failure; or
  12. with diabetes; or
  13. with Down syndrome; or
  14. who are pre-or post-splenectomy, or with functional asplenia.

Rectangle page icon symoblising a PDF. PDF
A tick icon. Fully subsidised
An oval with the number 29 in it. Unapproved medicine under Section 29
An asterisk symbol. 3 or 6 months should be dispensed at once
Two duplicate pages icon. Click to copy
A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
OP Original pack
Sole Subsidised Supply